David J Hughes1, Talita Duarte-Salles2, Sandra Hybsier3, Antonia Trichopoulou4, Magdalena Stepien5, Krasimira Aleksandrova6, Kim Overvad7, Anne Tjønneland8, Anja Olsen8, Aurélie Affret9, Guy Fagherazzi9, Marie-Christine Boutron-Ruault9, Verena Katzke10, Rudolf Kaaks10, Heiner Boeing6, Christina Bamia4, Pagona Lagiou11, Eleni Peppa12, Domenico Palli13, Vittorio Krogh14, Salvatore Panico15, Rosario Tumino16, Carlotta Sacerdote17, Hendrik Bastiaan Bueno-de-Mesquita18, Petra H Peeters19, Dagrun Engeset20, Elisabete Weiderpass21, Cristina Lasheras22, Antonio Agudo23, Maria-José Sánchez24, Carmen Navarro25, Eva Ardanaz26, Miren Dorronsoro27, Oskar Hemmingsson28, Nicholas J Wareham29, Kay-Tee Khaw30, Kathryn E Bradbury31, Amanda J Cross32, Marc Gunter32, Elio Riboli32, Isabelle Romieu5, Lutz Schomburg3, Mazda Jenab5. 1. Department of Physiology and Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland; davidhughes@rcsi.ie. 2. Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France; Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain; 3. Institut für Experimentelle Endokrinologie, Charité-Universitätsmedizin Berlin, Berlin, Germany; 4. Hellenic Health Foundation, Athens, Greece; WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology, and Medical Statistics, University of Athens Medical School, Athens, Greece; 5. Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France; 6. Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Nuthetal, Germany; 7. Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark; 8. Danish Cancer Society Research Center, Copenhagen, Denmark; 9. Institut National de la Santé et de la Recherche Médicale (INSERM), CESP Center for Research in Epidemiology and Population Health, U1018, Villejuif, France; Université Paris Sud, UMRS 1018, Villejuif, France; Institute Gustave Roussy, Villejuif, France; 10. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 11. Hellenic Health Foundation, Athens, Greece; WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology, and Medical Statistics, University of Athens Medical School, Athens, Greece; Department of Epidemiology, Harvard School of Public Health, Boston, MA; 12. Hellenic Health Foundation, Athens, Greece; 13. Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute-ISPO, Florence, Italy; 14. Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 15. Dipartimento di Medicina Clinica e Chirurgia Federico II, Naples, Italy; 16. Cancer Registry and Histopathology Unit, "Civic-M.P. Arezzo" Hospital, ASP Ragusa, Italy; 17. Unit of Cancer Epidemiology, Citta' della Salute e della Scienza Hospital-University of Turin and Center for Cancer Prevention, Turin, Italy; 18. Department for Determinants of Chronic Diseases, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom; 19. Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands; MRC-PHE Centre for Environment and Health. 20. The Norwegian Scientific Committee for Food Safety (VKM), Oslo, Norway; 21. Department of Community Medicine, Faculty of Health Sciences, University of Tromsø-The Arctic University of Norway, Tromsø, Norway; Department of Research, Cancer Registry of Norway, Oslo, Norway; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland; 22. Oviedo University, Oviedo, Spain; 23. Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; 24. Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs Granada, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain; Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; 25. CIBER de Epidemiología y Salud Pública (CIBERESP), Spain; Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain; Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain; 26. CIBER de Epidemiología y Salud Pública (CIBERESP), Spain; Navarra Public Health Institute, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; 27. Public Health Direction and Biodonostia-Ciberesp, Basque Regional Health Department, San Sebastian, Spain; 28. Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden; 29. MRC Epidemiology Unit and. 30. Clinical Gerontology, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom; and. 31. Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. 32. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom;
Abstract
BACKGROUND: Selenium status is suboptimal in many Europeans and may be a risk factor for the development of various cancers, including those of the liver and biliary tract. OBJECTIVE: We wished to examine whether selenium status in advance of cancer onset is associated with hepatobiliary cancers in the EPIC (European Prospective Investigation into Cancer and Nutrition) study. DESIGN: We assessed prediagnostic selenium status by measuring serum concentrations of selenium and selenoprotein P (SePP; the major circulating selenium transfer protein) and examined the association with hepatocellular carcinoma (HCC; n = 121), gallbladder and biliary tract cancers (GBTCs; n = 100), and intrahepatic bile duct cancer (IHBC; n = 40) risk in a nested case-control design within the EPIC study. Selenium was measured by total reflection X-ray fluorescence, and SePP was determined by a colorimetric sandwich ELISA. Multivariable ORs and 95% CIs were calculated by using conditional logistic regression. RESULTS: HCC and GBTC cases, but not IHBC cases, showed significantly lower circulating selenium and SePP concentrations than their matched controls. Higher circulating selenium was associated with a significantly lower HCC risk (OR per 20-μg/L increase: 0.41; 95% CI: 0.23, 0.72) but not with the risk of GBTC or IHBC. Similarly, higher SePP concentrations were associated with lowered HCC risk only in both the categorical and continuous analyses (HCC: P-trend ≤ 0.0001; OR per 1.5-mg/L increase: 0.37; 95% CI: 0.21, 0.63). CONCLUSION: These findings from a large prospective cohort provide evidence that suboptimal selenium status in Europeans may be associated with an appreciably increased risk of HCC development.
BACKGROUND:Selenium status is suboptimal in many Europeans and may be a risk factor for the development of various cancers, including those of the liver and biliary tract. OBJECTIVE: We wished to examine whether selenium status in advance of cancer onset is associated with hepatobiliary cancers in the EPIC (European Prospective Investigation into Cancer and Nutrition) study. DESIGN: We assessed prediagnostic selenium status by measuring serum concentrations of selenium and selenoprotein P (SePP; the major circulating selenium transfer protein) and examined the association with hepatocellular carcinoma (HCC; n = 121), gallbladder and biliary tract cancers (GBTCs; n = 100), and intrahepatic bile duct cancer (IHBC; n = 40) risk in a nested case-control design within the EPIC study. Selenium was measured by total reflection X-ray fluorescence, and SePP was determined by a colorimetric sandwich ELISA. Multivariable ORs and 95% CIs were calculated by using conditional logistic regression. RESULTS:HCC and GBTC cases, but not IHBC cases, showed significantly lower circulating selenium and SePP concentrations than their matched controls. Higher circulating selenium was associated with a significantly lower HCC risk (OR per 20-μg/L increase: 0.41; 95% CI: 0.23, 0.72) but not with the risk of GBTC or IHBC. Similarly, higher SePP concentrations were associated with lowered HCC risk only in both the categorical and continuous analyses (HCC: P-trend ≤ 0.0001; OR per 1.5-mg/L increase: 0.37; 95% CI: 0.21, 0.63). CONCLUSION: These findings from a large prospective cohort provide evidence that suboptimal selenium status in Europeans may be associated with an appreciably increased risk of HCC development.
Authors: Lori C Sakoda; Barry I Graubard; Alison A Evans; W Thomas London; Wen-Yao Lin; Fu-Min Shen; Katherine A McGlynn Journal: Int J Cancer Date: 2005-07-01 Impact factor: 7.396
Authors: E Riboli; K J Hunt; N Slimani; P Ferrari; T Norat; M Fahey; U R Charrondière; B Hémon; C Casagrande; J Vignat; K Overvad; A Tjønneland; F Clavel-Chapelon; A Thiébaut; J Wahrendorf; H Boeing; D Trichopoulos; A Trichopoulou; P Vineis; D Palli; H B Bueno-De-Mesquita; P H M Peeters; E Lund; D Engeset; C A González; A Barricarte; G Berglund; G Hallmans; N E Day; T J Key; R Kaaks; R Saracci Journal: Public Health Nutr Date: 2002-12 Impact factor: 4.022
Authors: Mohamed E Moustafa; Bradley A Carlson; Miriam R Anver; Gerd Bobe; Nianxin Zhong; Jerrold M Ward; Christine M Perella; Victoria J Hoffmann; Keith Rogers; Gerald F Combs; Ulrich Schweizer; Glenn Merlino; Vadim N Gladyshev; Dolph L Hatfield Journal: PLoS One Date: 2013-02-27 Impact factor: 3.240